RxDoctor Payments Data

Thomas McDonald, MD

Neurology · Colorado Springs, CONPI 1710956289

Payments from drug & device makers

$30,640in general payments, 2019–2025

Across 549 payments — averaging $55.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$17K
  • AbbVie$2K
  • Regeneron$1K
  • Pfizer$908
  • EMD Serono, Inc.$732
  • AstraZeneca$677
  • plus $8K from 54 others

What the payments were for

  • Consulting fees$1501%
  • Speaking & faculty fees$1201%
  • Food & beverage$11,50894%
  • Education$4514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly1$17,300
AbbVie(2 entities)82$1,588
Regeneron1$1,000
Pfizer66$908
EMD Serono, Inc.33$732
AstraZeneca(2 entities)28$677
Jazz Pharmaceuticals Inc.15$581
Neurocrine Biosciences, Inc.19$495
Biogen15$439
Novartis25$433
Merz Pharmaceuticals, LLC16$407
UCB, Inc.14$403
SK Life Science, Inc.13$381
Harmony Biosciences LLC10$372
Eisai Inc.16$368
Sanofi10$311
Amgen(2 entities)11$291
TG Therapeutics, Inc.19$279
Lilly USA, LLC14$238
Argenx US, Inc.9$225
Tanabe Pharma America, Inc.9$222
Ipsen Biopharmaceuticals, Inc8$176
Vanda Pharmaceuticals Inc.5$171
Genentech USA, Inc.6$164
Biohaven Pharmaceutical Holding Company Ltd.8$155
Acadia Pharmaceuticals Inc6$141
Neurelis, Inc.4$129
ANI Pharmaceuticals, Inc.5$126
Abbott6$125
Octapharma USA, Inc.5$115
Acorda Therapeutics, Inc3$113
Amneal Pharmaceuticals LLC4$107
MDD US Operations, LLC4$95
Bristol Myers Squibb3$93
Catalyst Pharmaceuticals, Inc.4$91
Avion Pharmaceuticals4$89
Alnylam Pharmaceuticals Inc.3$85
Otsuka America Pharmaceutical, Inc.4$84
Mallinckrodt Hospital Products Inc.3$71
Lundbeck LLC3$66
Collegium Pharmaceutical, Inc.3$66
Insightec,inc2$63
Banner Life Sciences, LLC3$57
Neuropace, Inc.2$50
Livanova USA, Inc.2$48
Avadel CNS Pharmaceuticals, LLC2$48
Ultragenyx Pharmaceutical Inc.2$42
Philips North America LLC1$42
Kyowa Kirin, Inc.2$40
Teva Pharmaceuticals USA, Inc.1$37
GRT US Holding, Inc.2$35
Merz North America, Inc.2$31
Nevro Corp.1$28
Grifols USA, LLC1$25
GE HealthCare1$25
Avanir Pharmaceuticals, Inc.1$23
Averitas Pharma Inc.1$22
Genentech, Inc.1$21
Vertical Pharmaceuticals, LLC1$21
CSL Behring1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,640 in reported general payments places this provider in the 75th percentile of 334 neurology providers in Colorado.

See all neurology providers in Colorado

Medicare billing

Part B allowed, 2024
$306,902
Medicare patients
550
Services billed
20,632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4640$285,208
XywavSodium,calcium,mag,pot Oxybate12$220,452
Sodium Oxybate12$207,815
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5022$206,717
AustedoDeutetrabenazine26$202,097
Radicava OrsEdaravone13$174,524
IngrezzaValbenazine Tosylate15$121,777
NuplazidPimavanserin Tartrate12$58,645
UbrelvyUbrogepant21$32,117
LamictalLamotrigine17$26,947
Oxtellar XrOxcarbazepine11$26,099
FelbatolFelbamate13$22,118
Topiramate ErTopiramate11$21,506
Lacosamide65$11,050
Ajovy AutoinjectorFremanezumab-Vfrm15$10,663

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$25$285,20840 claims
Teva Pharmaceuticals USA, Inc.Austedo$37$202,09726 claims
Neurocrine Biosciences, Inc.Ingrezza$495$121,77715 claims
Acadia Pharmaceuticals IncNuplazid$141$58,64512 claims
AbbVieUbrelvy$1,588$32,11721 claims
Amneal Pharmaceuticals LLCMycophenolate Mofetil$107$1,78723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 334 neurology providers in Colorado.

Other neurology in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →